03rd week of 2019 patent applcation highlights part 21 |
Patent application number | Title | Published |
20190016716 | Emetine Derivatives, Prodrugs Containing Same, And Methods Of Treating Conditions Using Same | 2019-01-17 |
20190016717 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | 2019-01-17 |
20190016718 | SALTS OF MORPHOLINE DERIVATIVE, CRYSTAL FORMS THEREOF, PROCESSES FOR PRODUCING THE SAME, PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME, AND USE THEREOF | 2019-01-17 |
20190016719 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | 2019-01-17 |
20190016720 | 7-OXO-6-(SULFOOXY)-1,6-DIAZABICYCLO[3.2.1]OCTANE-2-CARBOXAMIDE CONTAINING COMPOUNDS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | 2019-01-17 |
20190016721 | FUSED PYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF, AND USE THEREOF IN TREATMENT OF CANCERS, INFLAMMATION AND IMMUNE DISEASES | 2019-01-17 |
20190016722 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | 2019-01-17 |
20190016723 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | 2019-01-17 |
20190016724 | DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS | 2019-01-17 |
20190016725 | FORMS OF A PI3K DELTA SELECTIVE INHIBITOR FOR USE IN PHARMACEUTICAL FORMULATIONS | 2019-01-17 |
20190016726 | TDO2 Inhibitors | 2019-01-17 |
20190016727 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | 2019-01-17 |
20190016728 | BICYCLIC HETEROARYL DERIVATIVES AS CFTR POTENTIATORS | 2019-01-17 |
20190016729 | PROCESS FOR MAKING BETA 3 AGONISTS AND INTERMEDIATES | 2019-01-17 |
20190016730 | TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS | 2019-01-17 |
20190016731 | FUSED TETRA OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARP INHIBITORS | 2019-01-17 |
20190016732 | ACC INHIBITORS AND USES THEREOF | 2019-01-17 |
20190016733 | CRYSTALLINE FORMS OF THIENOPYRIMIDINE COMPOUND | 2019-01-17 |
20190016734 | C5-C6-Oxacyclic Fused Iminothiazine Dioxide Compounds Bearing an Ether Linker as BACE Inhibitors, Compositions, and Their Use | 2019-01-17 |
20190016735 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | 2019-01-17 |
20190016736 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | 2019-01-17 |
20190016737 | MECHANICALLY INTERLOCKED AIR-STABLE RADICALS | 2019-01-17 |
20190016738 | SUPRAMOLECULAR ASSEMBLY OF RIGID MACROCYCLES THROUGH COOPERATIVE HYDROGEN BOND INTERACTIONS | 2019-01-17 |
20190016739 | LIGHT-EMITTING COMPOUND | 2019-01-17 |
20190016740 | Metal Complexes, Comprising Carbene Ligands Having an O-Substituted Non-Cyclometalated Aryl Group and Their Use in Organic Light Emitting Diodes | 2019-01-17 |
20190016741 | SYMMETRICAL CCC-NHC PINCER METAL COMPLEXES AND SYMMETRICAL BIMETALLIC COMPLEXES: BIO-ACTIVITY, AND APPLICATIONS TO ORGANIC TRANSFORMATIONS AND ENERGY-RELATED CATALYTIC METHODS | 2019-01-17 |
20190016742 | Complexes | 2019-01-17 |
20190016743 | COMPOUNDS FOR INHIBITING CANCER AND VIRUS | 2019-01-17 |
20190016744 | PHENYLPROPANOID COMPOUND AND PREPARATION METHOD AND USE THEREOF | 2019-01-17 |
20190016745 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | 2019-01-17 |
20190016746 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | 2019-01-17 |
20190016747 | PURIFIED REBAUDIOSIDE A | 2019-01-17 |
20190016748 | COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION | 2019-01-17 |
20190016749 | 2'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | 2019-01-17 |
20190016750 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | 2019-01-17 |
20190016751 | COMPOSITIONS AND METHODS DIRECTED TO TREATING LIVER FIBROSIS | 2019-01-17 |
20190016752 | POLY(AMINO ACID), PROTEIN-POLY(AMINO ACID) CONJUGATE AND PREPARATION METHOD THEREOF | 2019-01-17 |
20190016753 | METHODS FOR SEPARATING ISOFORMS OF MONOCLONAL ANTIBODIES | 2019-01-17 |
20190016754 | METHODS OF PRODUCING AND PURIFYING MATRIX-BINDING FUSION PROTEINS BY ION-EXCHANGE CHROMATOGRAPHY | 2019-01-17 |
20190016755 | PROCESS FOR PRODUCTION OF FIBRINOGEN AND FIBRINOGEN PRODUCED THEREBY | 2019-01-17 |
20190016756 | NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS | 2019-01-17 |
20190016757 | ANTIMICROBIAL PEPTIDES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | 2019-01-17 |
20190016758 | Potent Compstatin Analogs | 2019-01-17 |
20190016759 | CAPSID-MODIFIED RAAV VECTOR COMPOSITIONS AND METHODS THEREFOR | 2019-01-17 |
20190016760 | Multimerization of Recombinant Protein by Fusion to a Sequence from Lamprey | 2019-01-17 |
20190016761 | Compositions and Vaccines Comprising Vesicles and Methods of Using the Same | 2019-01-17 |
20190016762 | LACTOBACILLUS ACIDOPHILUS SURFACE LAYER PROTEIN A (SLPA) AS A THERAPEUTIC AGENT FOR THE TREATMENT OF INFLAMMATORY DISEASES | 2019-01-17 |
20190016763 | Fibroin-Like Protein Variant and Cell Culture Method | 2019-01-17 |
20190016764 | FUSION POLYPEPTIDE IN WHICH ANTI-INFLAMMATORY POLYPEPTIDE AND FERRITIN MONOMER FRAGMENT ARE BOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING INFLAMMATORY DISEASES, CONTAINING SAME AS ACTIVE INGREDIENT | 2019-01-17 |
20190016765 | ENDOPLASMIC RETICULUM LOCALIZATION SIGNALS | 2019-01-17 |
20190016766 | Use of improved modulators of complement function as cancer therapeutics | 2019-01-17 |
20190016767 | MULTIMODAL TRAIL MOLECULES AND USES IN CELLULAR THERAPIES | 2019-01-17 |
20190016768 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | 2019-01-17 |
20190016769 | TISSUE PROTECTIVE PEPTIDES AND USES THEREOF | 2019-01-17 |
20190016770 | COMPOUNDS FOR INDUCING TISSUE FORMATION AND USES THEREOF | 2019-01-17 |
20190016771 | TRIMERIC COSTIMULATORY TNF FAMILY LIGAND-CONTAINING ANTIGEN BINDING MOLECULES | 2019-01-17 |
20190016772 | GM-CSF and IL-4 Conjugates, Compositions, and Methods Related Thereto | 2019-01-17 |
20190016773 | ENDOTHELIN-1 RECEPTOR BASED ENDOTHELIN-1 SPONGE | 2019-01-17 |
20190016774 | METHODS AND COMPOSITIONS RELATED TO GPCR AGONIST POLYPEPTIDES | 2019-01-17 |
20190016775 | Immunogenic Compositions | 2019-01-17 |
20190016776 | TUMOR-SPECIFIC IFNA SECRETION BY CAR T-CELLS TO REPROGRAM THE SOLID TUMOR MICROENVIRONMENT | 2019-01-17 |
20190016777 | T CELL RECEPTORS RECOGNIZING HLA-A1- OR HLA-CW7-RESTRICTED MAGE | 2019-01-17 |
20190016778 | TARGETED HETERODIMERIC Fc FUSION PROTEINS CONTAINING IL-15 IL-15alpha AND ANTIGEN BINDING DOMAINS | 2019-01-17 |
20190016779 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | 2019-01-17 |
20190016780 | CD27L COLLECTIN FUSION PROTEINS | 2019-01-17 |
20190016781 | POLYNUCLEOTIDES ENCODING IMMUNE MODULATING POLYPEPTIDES | 2019-01-17 |
20190016782 | STABLE FORM OF SIGNAL CONVERTING PROTEIN FUSION PROTEINS, AND METHODS OF USE AND PREPARATION THEREOF | 2019-01-17 |
20190016783 | METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS | 2019-01-17 |
20190016784 | MUTATED VON WILLEBRAND FACTOR | 2019-01-17 |
20190016785 | ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOF | 2019-01-17 |
20190016786 | BROADLY NEUTRALIZING HIV-1 ANTIBODIES THAT BIND TO THE CD4-BINDING SITE OF THE ENVELOPE PROTEIN | 2019-01-17 |
20190016787 | ANTIBODIES TO S. AUREUS SURFACE DETERMINANTS | 2019-01-17 |
20190016788 | ANTIBODY AND ANTIBODY-CONTAINING COMPOSITION | 2019-01-17 |
20190016789 | Antigen Binding Regions Against Fibronectin Type III Domains and Methods of Using The Same | 2019-01-17 |
20190016790 | RECOMBINANT PICP PROTEIN, AND METHOD FOR PREPARING ANTIBODY SPECIFICALLY BINDING THERETO | 2019-01-17 |
20190016791 | HIGH DOSE TREATMENTS FOR ALZHEIMER'S DISEASE | 2019-01-17 |
20190016792 | FC-REGION VARIANTS WITH MODIFIED FCRN-BINDING PROPERTIES | 2019-01-17 |
20190016793 | Albumin binding domain fusion proteins | 2019-01-17 |
20190016794 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | 2019-01-17 |
20190016795 | INHIBITION OF ALLERGIC REACTION USING AN IL-33 INHIBITOR | 2019-01-17 |
20190016796 | COMBINATION THERAPY COMPRISING A SUPERAGONISTIC ANTIBODY AGAINST INTERLEUKIN-2 AND A CHECKPOINT BLOCKADE AGENT | 2019-01-17 |
20190016797 | IMMUNE-STIMULATING HUMANIZED MONOCLONAL ANTIBODIES AGAINST HUMAN INTERLEUKIN-2, AND FUSION PROTEINS THEREOF | 2019-01-17 |
20190016798 | ANTI-NEUROTENSIN ANTIBODIES AND USES THEREOF | 2019-01-17 |
20190016799 | HUMAN PROGRAMMED CELL DEATH 1 RECEPTOR ANTIBODY, METHOD OF PREPARING SAME, AND USE THEREOF | 2019-01-17 |
20190016800 | ANTIBODIES BINDING LAG-3 AND USES THEREOF | 2019-01-17 |
20190016801 | DUAL SPECIFICITY POLYPEPTIDE MOLECULE | 2019-01-17 |
20190016802 | DUAL SPECIFICITY POLYPEPTIDE MOLECULE | 2019-01-17 |
20190016803 | DUAL SPECIFICITY POLYPEPTIDE MOLECULE | 2019-01-17 |
20190016804 | DUAL SPECIFICITY POLYPEPTIDE MOLECULE | 2019-01-17 |
20190016805 | ANTIBODY CONSTRUCTS FOR CDH19 AND CD3 | 2019-01-17 |
20190016806 | ANTI-PD-1 ANTIBODIES AND USES THEREOF | 2019-01-17 |
20190016807 | ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE | 2019-01-17 |
20190016808 | ANTI-EGFR COMBINATIONS FOR TREATING TUMORS | 2019-01-17 |
20190016809 | CXCR2 ANTIBODIES AND USES THEREOF | 2019-01-17 |
20190016810 | METHODS FOR TREATING OR PREVENTING GRAFT-VERSUS-HOST DISEASE INVOLVING THE ADMINISTRATION OF ANTI-CCR5 RECEPTOR AGENTS | 2019-01-17 |
20190016811 | ANTI-GARP PROTEIN AND USES THEREOF | 2019-01-17 |
20190016812 | NOVEL ANTI-TNFSF9 ANTIBODIES AND METHODS OF USE | 2019-01-17 |
20190016813 | ANTI-CD43 ANTIBODY AND USE THEREOF FOR CANCER TREATMENT | 2019-01-17 |
20190016814 | ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF USE THEREOF | 2019-01-17 |
20190016815 | ANTI-ENDOGLIN ANTIBODIES AND USES THEREOF | 2019-01-17 |